Elizabeth had a liver transplant two weeks ago. She is on immunosuppressive therapy. What side ...

Elizabeth had a liver transplant two weeks ago. She is on immunosuppressive therapy. What side effect of these medications might interfere with her nutrition status?
 a. Steatorrhea b. Hypoglycemia
  c. Gastroesophageal reflux d. Abdominal pain

Q. 2

Isabella is being evaluated for liver transplant surgery. The dietitian finds it difficult to assess her nutritional needs because:
 a. her weight may be incorrect due to fluid retention.
  b. her intake maybe inadequate due to esophageal varices.
  c. she is receiving nutrients via parenteral nutrition.
  d. she is suffering from steatorrhea.

Q. 3

Which of the following best describes the relationship between ammonia levels and hepatic encephalopathy?
 a. Although blood ammonia levels do not correlate well with the degree of neurological impairment in hepatic encephalopathy, ammonia-reducing medications can successfully reverse the neurological symptoms.
  b. Blood ammonia levels are positively correlated with the level of impairment, but their reduction rarely reverses the neurological symptoms.
  c. Blood ammonia levels increase only in the late stages of hepatic encephalopathy and can be treated with ammonia-reducing medications that will slow progression of the neurological impairments.
  d. Blood ammonia levels are inconsistently related to the extent of neurological impairments and their treatment has no appreciable effect on functioning.

Q. 4

Patients with stable cirrhosis usually require _____ kcal/kg per day,
 a. 5 to 15 b. 15 to 25
  c. 25 to 35 d. 35 to 45

Q. 5

What is a transjugular intrahepatic portosystemic shunt?
 a. A surgically created passage between the portal vein and hepatic vein
  b. An abnormal collateral arising as a result of prolonged portal systemic hypertension
  c. A surgically created passage between the portal artery and hepatic artery
  d. An implanted drain for abdominal ascites

Q. 6

Which of the following may be given to stimulate appetite and promote weight gain in patients with hepatitis?
 a. Furosemide b. Megestrol acetate
  c. Spironolactone d. Octreotide

Q. 7

Which of the following will reduce blood ammonia levels in patients with hepatitis?
 a. Dronabinol b. Megestrol acetate
  c. Lactulose d. Octreotide

Q. 8

Which of the following will reduce portal blood pressure and bleeding risk in patients with hepatitis?
 a. Dronabinol b. Rifaximin
  c. Lactulose d. Propranolol